Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement as effector system in cancer immunotherapy.

Paolo Macor1, Francesco Tedesco

  • 1Department of Physiology and Pathology, University of Trieste, Via Fleming 22, Trieste 34127, Italy.

Immunology Letters
|June 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma.

Nanomedicine (London, England)·2026
Same author

Pediatric endoscopic pilonidal sinus treatment (PEPSiT) as standard of care results over 10 years' experience in 507 patients.

Scientific reports·2026
Same author

Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Learning Curve of Docking Time in Robot-Assisted Radical Prostatectomy with the Hugo RAS System: How Many Procedures to Achieve Efficiency?

Journal of clinical medicine·2026
Same author

On the correlation between training modalities and recovery stages in poststroke robotic rehabilitation of the upper limb: a systematic review.

Journal of neuroengineering and rehabilitation·2026
Same journal

The dendritic cell identity crisis: why conflicting classifications demand a consensus framework?

Immunology letters·2026
Same journal

The malignancy within: what cancer teaches us about human bonds.

Immunology letters·2026
Same journal

Progranulin enhances complement component 5a-primed neutrophil activation in antineutrophil cytoplasmic antibody-associated vasculitis.

Immunology letters·2026
Same journal

The newly identified role of TRIM72, an E3 ligase, in NINJ1-mediated plasma membrane rupture: focus on its anti-inflammatory function.

Immunology letters·2026
Same journal

The subsets of circulating follicular helper T cells play an important role in the pathogenesis of Autoimmune thyroid diseases.

Immunology letters·2026
Same journal

Could bradykinin pathway inhibition change the course of severe hantavirus disease?

Immunology letters·2026
See all related articles

The complement system, a key part of immunity, shows great potential in cancer immunotherapy. Researchers are exploring ways to enhance its anti-tumour effects, particularly with modified antibodies and combinations targeting cancer cells.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • The role of the complement system in controlling tumor growth was historically underestimated, with a focus on cell-mediated immunity.
  • Monoclonal antibodies have revitalized interest in the complement system as a potent effector mechanism in cancer immunotherapy.

Purpose of the Study:

  • To explore the potential of the complement system as an effector mechanism in cancer immunotherapy.
  • To investigate strategies for enhancing complement-mediated anti-tumour activity.
  • To address challenges posed by complement regulatory proteins on tumor cells.

Main Methods:

  • Utilizing modified C-fixing antibodies with enhanced Fc portions for increased complement activation.
  • Employing combinations of antibodies targeting different molecules or epitopes on tumor cells.

Related Experiment Videos

  • Investigating the use of neutralizing antibodies against complement regulatory proteins alongside tumor-specific antibodies.

    • Main Results:

    • The complement system offers advantages due to its molecules' ability to penetrate tumor tissue and local component supply.
    • Modified antibodies and antibody combinations show promise in increasing complement activation efficiency against tumor cells.
    • Strategies to overcome complement evasion mechanisms, such as over-expressed regulatory proteins, are under active investigation.

    Conclusions:

    • The complement system is a promising effector mechanism in cancer immunotherapy.
    • Further research is focused on optimizing antibody-based strategies to enhance complement's anti-tumour efficacy.
    • Overcoming tumor cell evasion of complement attack is crucial for successful immunotherapy.